• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利用计算系统生物学方法鉴定 COVID-19 疾病机制中的药物靶点。

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches.

机构信息

Université Paris-Saclay, Laboratoire Européen de Recherche pour la Polyarthrite rhumatoïde - Genhotel, Univ Evry, Evry, France.

Lifeware Group, Inria, Saclay-île de France, Palaiseau, France.

出版信息

Front Immunol. 2024 Feb 13;14:1282859. doi: 10.3389/fimmu.2023.1282859. eCollection 2023.

DOI:10.3389/fimmu.2023.1282859
PMID:38414974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10897000/
Abstract

INTRODUCTION

The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing.

METHODS

Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors.

RESULTS

Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19.

DISCUSSION

The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies.

摘要

简介

COVID-19 疾病图谱项目是一项大型的社区努力，团结了来自全球 130 个机构的 277 名科学家。我们使用高质量、机械论的内容来描述 SARS-CoV-2 与宿主的相互作用，并开发可互操作的生物信息学管道，用于新的靶点识别和药物再利用。

方法

广泛的社区工作使系统生物学工具和平台之间的接口构建取得了令人瞩目的进展。我们的框架可以将来自组学数据分析和计算建模的生物分子与细胞、组织或患者特异性的失调途径联系起来。使用文本挖掘和 AI 辅助分析的药物再利用方法，确定了可能针对已识别关键因素的潜在药物、化学品和 microRNA。

结果

结果揭示了已经测试过抗 COVID-19 疗效的药物，为其作用机制提供了一个机制背景，以及已经在临床试验中用于治疗其他疾病的药物，从未针对 COVID-19 进行过测试。

讨论

关键的进展是，所提出的框架是多功能和可扩展的，为病毒-宿主相互作用和其他复杂病理提供了一个重要的升级。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/c9926f713501/fimmu-14-1282859-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/61073e34585b/fimmu-14-1282859-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/1e9b83154253/fimmu-14-1282859-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/df60fc202a29/fimmu-14-1282859-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/8df8ec25b52a/fimmu-14-1282859-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/72fc6b7d00e5/fimmu-14-1282859-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/874e36c94958/fimmu-14-1282859-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/6282ba24a1d8/fimmu-14-1282859-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/4c0fea1cc540/fimmu-14-1282859-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/3a66530ba512/fimmu-14-1282859-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/c9926f713501/fimmu-14-1282859-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/61073e34585b/fimmu-14-1282859-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/1e9b83154253/fimmu-14-1282859-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/df60fc202a29/fimmu-14-1282859-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/8df8ec25b52a/fimmu-14-1282859-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/72fc6b7d00e5/fimmu-14-1282859-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/874e36c94958/fimmu-14-1282859-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/6282ba24a1d8/fimmu-14-1282859-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/4c0fea1cc540/fimmu-14-1282859-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/3a66530ba512/fimmu-14-1282859-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f454/10897000/c9926f713501/fimmu-14-1282859-g010.jpg

相似文献

1
Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches.利用计算系统生物学方法鉴定 COVID-19 疾病机制中的药物靶点。
Front Immunol. 2024 Feb 13;14:1282859. doi: 10.3389/fimmu.2023.1282859. eCollection 2023.
2
COVID19 Disease Map, a computational knowledge repository of virus-host interaction mechanisms.COVID19 疾病图谱，一个病毒 - 宿主相互作用机制的计算知识库。
Mol Syst Biol. 2021 Oct;17(10):e10387. doi: 10.15252/msb.202110387.
3
Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.通过系统生物学方法和基于五个药物设计规范的 DNN-DTI 模型，重新利用多种分子药物治疗 COVID-19 相关急性呼吸窘迫综合征和非病毒性急性呼吸窘迫综合征。
Int J Mol Sci. 2022 Mar 26;23(7):3649. doi: 10.3390/ijms23073649.
4
Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.肺病网络揭示了合并症对 SARS-CoV-2 感染的影响和药物再利用的机会。
BMC Med Genomics. 2021 Sep 17;14(1):226. doi: 10.1186/s12920-021-01079-7.
5
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.探索 SARS-CoV-2 病毒-宿主-药物相互作用组以进行药物再利用。
Nat Commun. 2020 Jul 14;11(1):3518. doi: 10.1038/s41467-020-17189-2.
6
Repurposing of Anti-Cancer Drugs Against Moderate and Severe COVID Infection: A Network-Based Systems Biological Approach.抗癌药物再利用治疗中度和重度 COVID 感染：基于网络的系统生物学方法。
Niger J Clin Pract. 2024 Aug 1;27(8):950-957. doi: 10.4103/njcp.njcp_873_23. Epub 2024 Aug 26.
7
Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.针对 COVID-19 的计算机药物研发新兴策略：挑战与机遇。
Eur J Pharm Sci. 2020 Dec 1;155:105522. doi: 10.1016/j.ejps.2020.105522. Epub 2020 Aug 20.
8
Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model.生物信息学方法和仓鼠模型揭示甲氨蝶呤对 SARS-CoV-2 进入、感染和炎症的抑制作用。
Front Immunol. 2022 Dec 21;13:1080897. doi: 10.3389/fimmu.2022.1080897. eCollection 2022.
9
Bioinformatics and systems biology analysis revealed PMID26394986-Compound-10 as potential repurposable drug against covid-19.生物信息学和系统生物学分析表明，PMID26394986-Compound-10 可能成为治疗 COVID-19 的潜在再利用药物。
J Biomol Struct Dyn. 2024 Sep;42(15):7972-7985. doi: 10.1080/07391102.2023.2242500. Epub 2023 Aug 3.
10
Looking at COVID-19 from a Systems Biology Perspective.从系统生物学角度看 COVID-19。
Biomolecules. 2022 Jan 22;12(2):188. doi: 10.3390/biom12020188.

引用本文的文献

1
Unlocking liver physiology: comprehensive pathway maps for mechanistic understanding.揭开肝脏生理学的奥秘：用于机理理解的综合通路图
Front Toxicol. 2025 Jul 7;7:1619651. doi: 10.3389/ftox.2025.1619651. eCollection 2025.
2
Sustainable software development in science - insights from 20 years of Vanted.科学领域的可持续软件开发——来自20年Vanted的见解。
J Integr Bioinform. 2025 Jul 1;22(1). doi: 10.1515/jib-2025-0007. eCollection 2025 Mar 1.
3
In-silico study of approved drugs as potential inhibitors against 3CLpro and other viral proteins of CoVID-19.

本文引用的文献

1
DrugBank 6.0: the DrugBank Knowledgebase for 2024.DrugBank 6.0：2024 年版 DrugBank 知识库。
Nucleic Acids Res. 2024 Jan 5;52(D1):D1265-D1275. doi: 10.1093/nar/gkad976.
2
PhysiBoSS 2.0: a sustainable integration of stochastic Boolean and agent-based modelling frameworks.PhysiBoSS 2.0：随机布尔和基于主体建模框架的可持续集成。
NPJ Syst Biol Appl. 2023 Oct 30;9(1):54. doi: 10.1038/s41540-023-00314-4.
3
A large-scale Boolean model of the rheumatoid arthritis fibroblast-like synoviocytes predicts drug synergies in the arthritic joint.
对已批准药物作为针对新冠病毒3CL蛋白酶及其他病毒蛋白的潜在抑制剂的计算机模拟研究。
PLoS One. 2025 Jun 25;20(6):e0325707. doi: 10.1371/journal.pone.0325707. eCollection 2025.
4
FAIR assessment of Disease Maps fosters open science and scientific crowdsourcing in systems biomedicine.疾病图谱的FAIR评估促进了系统医学中的开放科学和科学众包。
Sci Data. 2025 May 23;12(1):851. doi: 10.1038/s41597-025-05147-w.
5
Advancing curation of viral life cycles, host interactions, and therapeutics in Reactome.推进Reactome中病毒生命周期、宿主相互作用及治疗方法的管理。
J Virol. 2025 May 20;99(5):e0202424. doi: 10.1128/jvi.02024-24. Epub 2025 Apr 23.
6
Cellular mechanical memory: a potential tool for mesenchymal stem cell-based therapy.细胞机械记忆：基于间充质干细胞治疗的潜在工具。
Stem Cell Res Ther. 2025 Mar 31;16(1):159. doi: 10.1186/s13287-025-04249-x.
7
Deciphering shared molecular dysregulation across Parkinson's disease variants using a multi-modal network-based data integration and analysis.使用基于多模态网络的数据整合与分析来解读帕金森病不同变体之间共享的分子失调情况。
NPJ Parkinsons Dis. 2025 Mar 31;11(1):63. doi: 10.1038/s41531-025-00914-3.
8
Immune digital twins for complex human pathologies: applications, limitations, and challenges.免疫数字孪生在复杂人类病理中的应用、局限性和挑战。
NPJ Syst Biol Appl. 2024 Nov 30;10(1):141. doi: 10.1038/s41540-024-00450-5.
大规模布尔模型的类风湿关节炎成纤维样滑膜细胞预测药物协同作用在关节炎关节。
NPJ Syst Biol Appl. 2023 Jul 15;9(1):33. doi: 10.1038/s41540-023-00294-5.
4
StonPy: a tool to parse and query collections of SBGN maps in a graph database.StonPy：一个在图数据库中解析和查询 SBGN 图集合的工具。
Bioinformatics. 2023 Mar 1;39(3). doi: 10.1093/bioinformatics/btad100.
5
NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.NLRP3炎性小体激活与新型冠状病毒介导的过度炎症、细胞因子风暴和神经综合征。
Int J Physiol Pathophysiol Pharmacol. 2022 Jun 15;14(3):138-160. eCollection 2022.
6
The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases.NLRP3炎性小体通路：炎症性疾病治疗的机制与抑制剂综述
Front Aging Neurosci. 2022 Jun 10;14:879021. doi: 10.3389/fnagi.2022.879021. eCollection 2022.
7
Addressing barriers in comprehensiveness, accessibility, reusability, interoperability and reproducibility of computational models in systems biology.解决系统生物学中计算模型在全面性、可及性、可重用性、互操作性和可重复性方面的障碍。
Brief Bioinform. 2022 Jul 18;23(4). doi: 10.1093/bib/bbac212.
8
Inflammasome activation in infected macrophages drives COVID-19 pathology.在被感染的巨噬细胞中激活炎症小体导致 COVID-19 病理学。
Nature. 2022 Jun;606(7914):585-593. doi: 10.1038/s41586-022-04802-1. Epub 2022 Apr 28.
9
Patient-specific Boolean models of signalling networks guide personalised treatments.基于信号网络的个体化布尔模型指导个体化治疗。
Elife. 2022 Feb 15;11:e72626. doi: 10.7554/eLife.72626.
10
Adverse Outcome in COVID-19 Is Associated With an Aggravating Hypo-Responsive Platelet Phenotype.新冠病毒病（COVID-19）的不良结局与血小板低反应性表型加重有关。
Front Cardiovasc Med. 2021 Dec 10;8:795624. doi: 10.3389/fcvm.2021.795624. eCollection 2021.